Nissui Pharmaceutical Co., Ltd. Stock

4550

JP3678100003

OTC Markets Traded

Latest news : Nissui Pharmaceutical Co., Ltd.

23/03/23	MiCAN Technologies Inc. announced that it has received ¥50 million in funding from Nissui Pharmaceutical Co., Ltd.	CI
19/09/22	Nissui Pharmaceutical Co., Ltd.(TSE:4550) dropped from S&P Global BMI Index	CI
06/09/22	Tranche Update on Nissui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 31, 2022.	CI
06/09/22	Tranche Update on Nissui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 31, 2022.	CI
05/09/22	Nissui Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 31, 2022 has closed with 12,552,248 shares, representing 55.67% for ¥20,861.84	CI
28/07/22	Shimadzu Corporation completed the acquisition of 34.7% stake in Nissui Pharmaceutical Co., Ltd. for ¥13.3 billion.	CI
31/05/22	Nissui Pharmaceutical Co., Ltd. announces an Equity Buyback for 13,237,063 shares, representing 58.71% for ¥22,000 million.	CI
31/05/22	Shimadzu Corporation made an offer to acquire a 45.9% stake in Nissui Pharmaceutical Co., Ltd. for ¥17.6 billion.	CI
31/05/22	Nissui Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	CI
27/03/21	Nissui Pharmaceutical Co., Ltd. cancelled the acquisition of 10% stake in Nihon Techno Service Co., Ltd. from Takashi Masaki.	CI
17/01/21	Zeria Pharmaceutical Co., Ltd. cancelled the agreement to acquire Nissui Pharm Medical Sales Co., Ltd. from Nissui Pharmaceutical Co., Ltd..	CI
21/09/20	Nissui Pharmaceutical Co., Ltd.(TSE:4550) added to S&P Global BMI Index	CI
27/03/20	Nissui Pharmaceutical Co., Ltd. agreed to acquire 10% stake in Nihon Techno Service Co., Ltd. from Takashi Masaki.	CI

More news

Press Releases : Nissui Pharmaceutical Co., Ltd.

27/07/22	Nissui Pharmaceutical : Consolidated Financial Results for the Three Months Ended June 30, 2022	PU
28/10/21	Consolidated Financial Results for the Six Months Ended September 30, 2021	PU
01/10/21	Announcement: Transition of distribution in Europe, Turkey and Africa	PU
18/02/21	Nissui Pharmaceutical : Consolidated Financial Results for the Nine Months Ended December 31, 2020	PU

More press releases

Managers and Directors : Nissui Pharmaceutical Co., Ltd.

Manager	Title	Age	Since
Tokuya Ono CEO	Chief Executive Officer	64	-
Tatsuo Ishii DFI	Director of Finance/CFO	-	01/06/2022
Yuichi Oku CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Eiichi Shibasaki BRD	Director/Board Member	70	01/06/2009
Tokuya Ono BRD	Director/Board Member	64	01/06/2011
Kazunori Kato BRD	Director/Board Member	63	24/06/2016

More insiders

Nissui Pharmaceutical Co.,Ltd. is a Japan-based company mainly engaged in the manufacture, purchase and sale of clinical diagnostic drugs, industrial diagnostic drugs, pharmaceuticals, among others. The Company operates through two business segments. The Diagnostic Drug segment is involved in the manufacture, purchase and sale of culture media, clinical diagnostic drugs, industrial diagnostic drugs and raw materials for medical institutions, research institutions and industrial facilities, as well as the purchase and sale of testing equipment and other equipment. The Pharmaceutical segment is involved in the manufacture, purchase and sale of pharmaceuticals and health foods for pharmacies and drugstores. The Company's main products include clinical diagnostic drugs, industrial diagnostic drugs such as compactdry, pharmaceuticals such as therapeutics, nourishing tonics and health foods.

Employees

239

Sector

More about the company